Introduction Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13
signaling. It is currently indicated for the treatment of asthma, moderate-to-severe atopic …

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease characterized by
eosinophil-rich granulomatous inflammation and necrotizing vasculitis, pre-dominantly …

Background Hypereosinophilic syndrome (HES) is a group of rare hematologic disorders
leading to eosinophil-driven tissue damage and dysfunction. Better understanding of HES …

After the emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the last two decades, the …

Over the past years, eosinophils have become a focus of scientific interest, especially in the
context of their recently uncovered functions (eg antiviral, anti‐inflammatory, regulatory) …

Background A double-blind, placebo-controlled, phase III study (200622) showed that
mepolizumab reduces disease flares for patients with uncontrolled FIP1-like-1-platelet …

Hypereosinophilic syndrome (HES) encompasses a heterogeneous and complex group of
different subtypes within the wider group of hypereosinophilic disorders. Despite increasing …

Eosinophilic respiratory disorders and the impact of biologi... : Current Opinion in Pulmonary
Medicine Eosinophilic respiratory disorders and the impact of biologics : Current Opinion in …

Purpose Biological therapies are gaining relevance in the management of CRSwNP with
few adverse events reported. Among these, dupilumab, an anti-IL4-Ra monoclonal antibody …

Background Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in
patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are …